Refine by
Small Molecule Drug Development With Protein Small Molecule Articles & Analysis
83 news found
BOC Sciences adds to its participation agenda the prestigious Drug Discovery Chemistry 2025 Conference (April 14-17, 2025), which will be a hybrid event taking place in San Diego, CA, and will offer virtual access for worldwide attendees Drug Discovery Chemistry is a heavyweight industry event. It draws thousands of scientists, biotech innovators, and pharmaceutical executives ...
In an era where technological advancements are constantly reshaping the landscape of the pharmaceutical industry, Protheragen-ING has emerged as a frontrunner with its cutting-edge AI-synthesizer for small molecule drug synthesis. This revolutionary platform is transforming traditional drug formulation processes by employing a unique combination of machine learning algorithms, advanced ...
In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its AI-powered drug discovery and design ...
RDCs leverage medical radionuclides to integrate treatment modalities with diagnostic capabilities, augmenting personalized medicine efforts. Small Molecule Drug Conjugates (SMDCs) service is also a significant part of CD Formulation’s portfolio. Utilizing small molecules for targeting, rather than ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. Following with the announcement of developing small molecule drug for glaucoma, Ace Therapeutics recently unveiled disease model customization services to accelerate ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...
Small molecules play a crucial role in modern drug discovery and development. ...
CD Formulation, a leading provider of contract pharmaceutical formulation development services, recently announced the launch of its dissolving microneedle preparation services. This breakthrough in drug delivery technology promises to revolutionize the way medications are administered, enhancing efficiency and patient comfort. Microneedles are tiny, painless needles that penetrate the skin's ...
Customization for Personalized Medicine: Antibodies are tailored to individual patient profiles, enhancing the potential for personalized medicine and increasing treatment efficacy while minimizing side effects. 5. Integration with Protein Drug Design: CD ComputaBio's platform seamlessly integrates Antibody De Novo Design with Protein ...
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...
In addition, Creative Diagnostics possesses a variety of ELISA kits for the detection of hundreds of different proteins and molecules, including cytokines, growth factors, markers of infectious diseases, diabetes and tumors, small molecular drugs, and more. ...
Small molecule drug development faces various challenges, such as drug toxicity, instability, and resistance. ...
For larger genes (>5Kb) the company has developed the innovative REVeRT vector platform. This platform uses an innovative vector approach to pack split genes into individual vgAAV vectors and generate a full-length protein via mRNA trans-splicing. ...
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...
ByBayer AG
About Proteros biostructures GmbH Proteros is a privately-held company with expertise in structure-based drug discovery powered by a cutting-edge discovery engine tailored to unlock even the most technically challenging disease-relevant drug targets. The company provides small molecule drug discovery services ...
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...
One-stop Solution for Small Molecule Drug Formulation Small molecules make up the majority of current drugs used to treat and control conditions like cancer, infections and depression. CD Formulation has developed technologies to simplify the development of ...
” “Despite decades of effort, many targets remain inaccessible to traditional small molecule drugs, and many others have uncertain relevance to disease,” said Vividion Therapeutics CEO Jeffrey Hatfield. ...
ByBayer AG
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. Levinson, today announced a research collaboration to discover and develop small molecule ...